Latest news, press releases, and SEC filings for Alterity Therapeutics Limited (PRNAF) https://caymanjournal.com/stock/PRNAF en-us Copyright 2026, Cayman Journal editorial@caymanjournal.com (Editorial Team) webmaster@caymanjournal.com (Web Master) Wed, 29 Jul 2026 17:41:03 GMT 60 https://caymanjournal.com/logo.png https://caymanjournal.com 144 144 # 📰 What This Document Is 🔬 This document is a Form 6-K filing (an international filing required by the SEC) that serves as a press release. It communicates critical clinical data results from Alterity Therapeutics' lead drug candidate, ATH434. Essentially, Alterity presented new, detailed finding https://caymanjournal.com/stock/PRNAF/sec-filing/0001437749-26-012959 https://caymanjournal.com/stock/PRNAF/sec-filing/0001437749-26-012959 Wed, 22 Apr 2026 00:00:00 GMT SEC Filing # 🧾 What This Document Is This is a **6-K form**, which foreign companies like Australian-based Alterity use to report major events to the U.S. SEC. This specific filing contains an exhibit—a press release announcing **positive feedback from the FDA** about their drug development plan. It’s a regu https://caymanjournal.com/stock/PRNAF/sec-filing/0001437749-26-010134 https://caymanjournal.com/stock/PRNAF/sec-filing/0001437749-26-010134 Mon, 30 Mar 2026 00:00:00 GMT SEC Filing